MAPT and early-onset autosomal dominant Alzheimer disease: Blood‐based biomarkers (BBMs) for Alzheimer's disease (AD), including plasma phosphorylated tau (p‐tau), are increasingly used in clinical practice, but “real‐world” implementation patterns, context‐of‐use (COU), clinical utility, and diagnostic performance are incompletely understood.